[HTML][HTML] Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

…, P Skolnick, D Deaver, MJ Millan, JF Bastlund… - Nature Reviews Drug …, 2016 - nature.com
A recent article identified five key technical determinants that make substantial contributions
to the outcome of drug R&D projects (Lessons learned from the fate of AstraZeneca’s drug …

Therapeutic potential of NaV1. 1 activators

HS Jensen, M Grunnet, JF Bastlund - Trends in pharmacological sciences, 2014 - cell.com
Sodium channel inhibitors have been developed and approved as drugs to treat a variety of
indications. By contrast, sodium channel activators have not previously been considered …

Structure− activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5 …

…, THV Huynh, B Abrahamsen, JF Bastlund… - Journal of medicinal …, 2010 - ACS Publications
The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous
system, where they are responsible for the reuptake of the excitatory neurotransmitter (S)-…

A mouse model that recapitulates cardinal features of the 15q13. 3 microdeletion syndrome including schizophrenia-and epilepsy-related alterations

K Fejgin, J Nielsen, MR Birknow, JF Bastlund… - Biological …, 2014 - Elsevier
Background Genome-wide scans have uncovered rare copy number variants conferring high
risk of psychiatric disorders. The 15q13.3 microdeletion is associated with a considerably …

Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11. 2 microdeletion syndrome: a …

…, J Egebjerg, F Gastambide, F Artigas, JF Bastlund… - Journal of Psychiatry and …, 2017 - jpn.ca
Background: The hemizygous 22q11.2 microdeletion is a common copy number variant in
humans. The deletion confers high risk for neurodevelopmental disorders, including autism …

Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS

…, R Becker, M Didriksen, JF Bastlund… - Nature Reviews Drug …, 2017 - nature.com
Despite the vast amount of research on schizophrenia and depression in the past two decades,
there have been few innovative drugs to treat these disorders. Precompetitive research …

[HTML][HTML] A mouse model of the 15q13. 3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment

…, TW Robbins, JF Bastlund, TJ Bussey, F Artigas… - …, 2016 - Springer
Rationale A microdeletion at locus 15q13.3 is associated with high incidence rates of
psychopathology, including schizophrenia. A mouse model of the 15q13.3 microdeletion syndrome …

A multifaceted GABAA receptor modulator: functional properties and mechanism of action of the sedative-hypnotic and recreational drug methaqualone (quaalude)

…, OHU Schroeder, JF Bastlund… - Molecular …, 2015 - ASPET
In the present study, we have elucidated the functional characteristics and mechanism of
action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude), an infamous …

[HTML][HTML] Characterization of amphetamine, methylphenidate, nicotine, and atomoxetine on measures of attention, impulsive action, and motivation in the rat …

…, C Mombereau, H Lindgren, JF Bastlund - Frontiers in …, 2020 - frontiersin.org
Amphetamine (AMP), methylphenidate (MPH), and atomoxetine (ATX) are approved treatments
for ADHD, and together with nicotine (NIC), represent pharmacological agents widely …

Pharmaco‐electroencephalographic responses in the rat differ between active and inactive locomotor states

…, C Agerskov, L Arvastson, JF Bastlund… - European Journal of …, 2019 - Wiley Online Library
Quantitative electroencephalography from freely moving rats is commonly used as a translational
tool for predicting drug‐effects in humans. We hypothesized that drug‐effects may be …